This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Statistics and Research Methods  • Transplantation  • Transplantation, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: In their Clinical Review, Dr Burt and colleagues¹ assessed clinical applications of adult stem cell therapies for nonmalignant diseases. They acknowledge modest benefit from hematopoietic stem cell transplantation in cardiac disease and ameliorative but noncurative outcomes in autoimmune diseases. Although we agree that greater investments are needed in the clinical development of these therapies, we disagree with the authors' suggestion that, relative to embryonic stem cells, adult stem cells provide a superior vehicle for cell-based therapies because they lack tumorigenic activity, can be prepared by methods approved by the Food and Drug Administration (FDA), and have been free of ethical controversy. It would have been more appropriate to note that their review targeted hematopoietic stem cell transplantation because embryonic stem cells are not yet ready for clinical use.

Their conclusion discounts reports of improving preparative methods for embryonic stem cells that may lend themselves to future FDA-approvable . . . [Full Text of this Article]

Steven Teitelbaum, MD
teitelbs@wustl.edu
Department of Pathology and Immunology
Washington University
St Louis, Missouri

Shane Smith, PhD
Children's Neurobiological Solutions Foundation
Santa Barbara, California

William Neaves, PhD
Stowers Institute for Medical Research
Kansas City, Missouri

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?